Retinal Pigment Epithelial Detachment in Central Serous Chorioretinopathy

  • Mathias MaierEmail author


In 1866, Albrecht von Graefe described a disease, which he called “recurrent central retinitis” [1]. Patients suffering from this condition showed a circumscribed serous retinal detachment typically affecting the posterior pole [1–3]. Since then, several publications with further definitions and terminologies of this disease followed.


  1. 1.
    Graefe A. Über die zentrale rezidivierende retinitis. Graefes Arch Ophthalmol. 1866;12:211–5.CrossRefGoogle Scholar
  2. 2.
    Baraki H, Feltgen N, Roider J, Hoerauf H, Klatt C. Central serous chorioretinopathy (CSC). Ophthalmologe. 2010;107:479–92.CrossRefPubMedGoogle Scholar
  3. 3.
    Liegl R, Ulbig MW. Central serous chorioretinopathy. Ophthalmologica. 2014;232(2):65–76.CrossRefPubMedGoogle Scholar
  4. 4.
    Maumenee AE. Macular diseases: clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:605–13.PubMedGoogle Scholar
  5. 5.
    Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967;63(3):Suppl:1–139.Google Scholar
  6. 6.
    Wang M, Munch IC, Hasler PW, Prünte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126–45.CrossRefPubMedGoogle Scholar
  7. 7.
    Klein ML, Van Buskirk EM, Friedman E, Gragoudas E, Chandra S. Experience with nontreatment of central serous choroidopathy. Arch Ophthalmol. 1974;91(4):247–50.CrossRefPubMedGoogle Scholar
  8. 8.
    Valet V, Lohmann CP, Maier M. Spectral domain OCT in central serous chorioretinopathy: description of retinal changes. Ophthalmologe. 2012;109(9):879–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Kim HC, Cho WB, Chung H. Morphologic changes in acute central serous chorioretinopathy using spectral domain optical coherence tomography. Korean J Ophthalmol. 2012;26(5):347–54.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shinojima A, Hirose T, Mori R, et al. Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina. 2010;30:193–202.CrossRefPubMedGoogle Scholar
  11. 11.
    Chan WM, et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Chen SN, et al. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115:2229–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Elsner H, et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244:1638–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Forooghian F, Meleth AD, Cukras C, Chew EY, Wong WT, Meyerle CB. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31(4):766–71.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Framme C, et al. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005;83:161–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Fujimoto H, Gomi F, Wakabayashi T, et al. Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography. Ophthalmology. 2008;115:1494–500, 1500.e1–2.Google Scholar
  17. 17.
    Maier M, Valet V, Feucht N, Lohmann CP. Therapy options for chronic central serous chorioretinopathy. Photodynamic therapy combined with bevacizumab—a case series. Ophthalmologe. 2011;108(11):1027–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Abouammoh MA. Advances in the treatment of central serous chorioretinopathy. Saudi J Ophthalmol. 2015;29:278–86.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gupta P, et al. Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy. Int Ophthalmol. 2010;30:175–81.CrossRefPubMedGoogle Scholar
  20. 20.
    Kamppeter B, Jonas JB. Central serous chorioretinopathy imaged by optical coherence tomography. Arch Ophthalmol. 2003;121:742–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231–42.CrossRefPubMedGoogle Scholar
  22. 22.
    Prünte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996;121(1):26–34.CrossRefPubMedGoogle Scholar
  23. 23.
    Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16:203–13.CrossRefPubMedGoogle Scholar
  24. 24.
    Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa DL, Huang SJ, Klancnik Jr JM, Aizman A. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23:288–98.CrossRefPubMedGoogle Scholar
  25. 25.
    Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149:361–3.CrossRefPubMedGoogle Scholar
  26. 26.
    Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Kukui K, Ishiko S, Yoshida A. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol. 2003;87:709–12.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Imamura Y, Fujuwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29:1469–73.CrossRefPubMedGoogle Scholar
  28. 28.
    Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103:2070–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Goldstein BG, Pavan PR. ‘Blow-outs’ in the retinal pigment epithelium. Br J Ophthalmol. 1987;71(9):676–81.Google Scholar
  30. 30.
    Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy. A pilot study. Retina. 2013;33(10):2096–102.CrossRefPubMedGoogle Scholar
  31. 31.
    Maier M, Stumpfe S, Feucht N, Strobl P, Rath V, Lohmann CP. Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy. Ophthalmologe. 2014;111(2):173–80.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhao M, Célérier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122(7):2672–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Miki A, Kondo N, Yanagisawa S, Bessho H, Honda S, Negi A. Common variants in the complement factor h gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–72.CrossRefPubMedGoogle Scholar
  34. 34.
    Matsumoto H, Kishi S, Otani T, Sato T. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol. 2008;145:162–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Matsumoto H, Sato T, Kishi S. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy. Am J Ophthalmol. 2009;148:105–10.e1.Google Scholar
  36. 36.
    Mitarai K, Gomi F, Tano Y. Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244:1415–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Montero JA, Ruiz-Moreno JM. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy. Br J Ophthalmol. 2005;89:562–4.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Brandl C, Helbig H, Gamulescu MA. Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol. 2014;34(1):7–13.CrossRefPubMedGoogle Scholar
  39. 39.
    Maruko I, Iida T, Sugano Y, Ojima A, Ogawawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117:1792–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Lai TYY, Chan W-M, Li H, Lai RYK, Liu DTL, Lam DSC. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. 2006;90(7):869–74.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Verma L, Sinha R, Venkatesh P, Tewari HK. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial ISRCTN84128484. BMC Ophthalmol. 2004;4:15.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Meyerle CB, Freund KB, Bhatnagar P, Shah V, Yannuzzi LA. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina. 2007;27:943–6.CrossRefPubMedGoogle Scholar
  43. 43.
    Schaal KB, Hoeh AE, Scheuerle A, Schuett F, Dithmar S. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009;19:613–7.PubMedGoogle Scholar
  44. 44.
    Bae SH, Heo J, Kim C, et al. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Ophthalmology. 2014;121(2):558–65.CrossRefPubMedGoogle Scholar
  45. 45.
    Chan WM, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87:1453–8.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Pikkel J, Beiran I, Ophir A, et al. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109:1723–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Shibata A, Ohkuma Y, Hayashi T, Tsuneoka H. Efficacy of reduced-fluence photodynamic therapy for serous retinal pigment epithelial detachment with choroidal hyperpermeability. Clin Ophthalmol. 2013;7:2123–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Shukla D, Kolluru C, Vignesh TP, Karthikprakash S, Kim R. Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy. Eye (Lond). 2008;22(1):100–6.CrossRefGoogle Scholar
  49. 49.
    Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47:431–48.CrossRefPubMedGoogle Scholar
  50. 50.
    Novak MA, Singerman LJ, Rice TA. Krypton and argon laser photocoagulation for central serous chorioretinopathy. Retina. 1987;7(3):162–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457–66.CrossRefPubMedGoogle Scholar
  52. 52.
    Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Experiment Ophthalmol. 2009;37(8):801–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Brinkmann R, Schule G, Neumann J, et al. Selektive Retinatherapie: Methodik, Technik und Online-Dosimetrie. Ophthalmologe. 2006;103:839–49.CrossRefPubMedGoogle Scholar
  54. 54.
    Ruiz-Moreno JM, Lugo FL, Armadá F, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol. 2010;88(3):371–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Lim JW, Kang SW, Kim Y-T, Chung SE, Lee SW. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol. 2011;95(4):514–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010;149(2):307–15.CrossRefPubMedGoogle Scholar
  57. 57.
    Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina. 2011;31(9):1937–43.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Leitender Oberarzt und stellv. Direktor, Klinik und Poliklinik für AugenheilkundeKlinikum rechts der Isar, Technische Universität MünchenMünchenGermany

Personalised recommendations